结核病治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

由于潜伏性结核病 (TB) 病例盛行率不断上升，结核病治疗市场预计在 2024 年至 2032 年期间复合年增长率为 4.1%。据 NCBI 称，目前世界上大约 25% 的人口感染了潜伏的结核分枝桿菌。据估计，世界上近四分之一的人口感染了潜伏性结核病，因此迫切需要有效的治疗解决方案来防止进展为活动性结核病。这推动了对创新治疗的需求，这些治疗旨在在潜在感染活跃之前瞄准并根除它们。

人们越来越重视合併治疗以提高治疗效果。合併治疗对于治疗多重抗药性 (MDR) 和广泛抗药性 (XDR) 结核病尤其重要，而单一药物治疗往往达不到这些要求。最近的发展催生了针对结核病感染多个方面的新药物组合，减少了抗药性的可能性并改善了患者的整体治疗结果。这些合併治疗方案缩短了治疗时间，增强了药物有效性，并提高了患者的依从性。

结核病治疗产业根据疾病类型、治疗方法、给药途径、剂型、配销通路和地区进行分类。

到 2032 年，潜伏性结核病部分将迅速增长，因为在这个阶段，细菌不活跃，不会引起症状，但可以在以后重新激活，这对公共卫生提出了重大挑战。潜伏结核病病例的增加推动了对新的和改进的治疗方案的需求，以有效防止疾病的进展。药物开发的最新进展导致了专门针对潜伏性结核病的新型治疗药物和联合疗法的推出。

由于药物吸收快、治疗效果立竿见影以及对剂量的精确控制，到 2032 年，肠外给药领域将获得相当大的牵引力。由于需要更有效和可靠的治疗选择，特别是对于多重抗药性（MDR）和广泛抗药性（XDR）结核病病例，结核病治疗中对肠外给药的关注日益增加。肠外製剂和给药系统的最新创新提高了药物稳定性，提高了患者便利性，并最大限度地减少了副作用。

在结核病研究资金增加、宣传活动提高以及先进医疗保健政策实施的推动下，欧洲结核病治疗产业规模将在 2024 年至 2032 年快速成长。该地区各国对创新结核病疗法和改进诊断工具以有效对抗疾病的需求不断增长。强大的医疗保健基础设施支持新治疗方式和药物传输系统的广泛采用，将促进欧洲结核病治疗市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 结核病患率上升
    • 加大医疗基础建设投资
    • 研究和开发活动的增加
    • 意识和倡议不断增强
  • 产业陷阱与挑战
    • 治疗费用高
• 成长潜力分析
• 监管环境
• 报销场景
• 技术景观
• 未来市场趋势
• 管道分析
• 差距分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 供应商矩阵分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按疾病类型，2021 - 2032

• 主要趋势
• 活动性结核病
• 潜伏性结核病

第 6 章：市场估计与预测：按疗法分类，2021 - 2032 年

• 主要趋势
• 一线治疗
• 二线治疗

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

• 主要趋势
• 口服
• 注射用
• 其他给药途径

第 8 章：市场估计与预测：按剂型，2021 - 2032

• 主要趋势
• 平板电脑
• 胶囊
• 注射
• 其他剂型

第 9 章：市场估计与预测：按配销通路，2021 - 2032

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 10 章：市场估计与预测：按地区划分，2021 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 11 章：公司简介

• Aventis Pharmaceuticals Limited
• Bayer Health Care
• Eli Lilly And Company
• Johnson and Johnson Services; Inc.
• Lupin
• Macleods Pharmaceuticals Ltd.
• Mylan N.V.
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Sanofi.

The Tuberculosis Therapeutics Market is poised to register a 4.1% CAGR during 2024-2032, driven by the increasing prevalence of latent tuberculosis (TB) cases. According to NCBI, approximately 25% of the world's population is currently infected with Mycobacterium tuberculosis in a latent form. With nearly one-quarter of the world's population estimated to be infected with latent TB, there is an urgent need for effective therapeutic solutions to prevent the progression to active TB. This is pushing the demand for innovative treatments designed to target and eradicate latent infections before they become active.

There is a growing emphasis on combination therapy to enhance treatment outcomes. Combination therapy is particularly significant for treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB, where single-drug therapies often fall short. Recent developments have led to new drug combinations that target multiple aspects of TB infection, reducing the likelihood of resistance and improving overall patient outcomes. These combination regimens shorten treatment duration, enhance drug effectiveness, and improve patient adherence.

The tuberculosis therapeutics industry is classified based on disease type, therapy, route of administration, dosage form, distribution channel, and region.

The latent tuberculosis segment will grow rapidly through 2032, as it is a stage where the bacteria are inactive and not causing symptoms but can reactivate later, which presents a significant challenge for public health. The rise in latent TB cases is driving the demand for new and improved treatment regimens that can effectively prevent the progression of the disease. Recent advancements in drug development have led to the introduction of novel therapeutic agents and combination therapies specifically targeting latent TB.

The parenteral administration segment will witness decent traction through 2032, owing to rapid drug absorption, immediate therapeutic effects, and precise control over dosage. The increasing focus on parenteral administration in TB therapeutics is driven by the need for more effective and reliable treatment options, especially for multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB cases. Recent innovations in parenteral formulations and delivery systems have improved drug stability, enhanced patient convenience, and minimized side effects.

Europe tuberculosis therapeutics industry size will grow rapidly over 2024-2032, driven by increased funding for TB research, heightened awareness campaigns, and the implementation of advanced healthcare policies. Countries within the region are experiencing a growing demand for innovative TB therapies and improved diagnostic tools to combat the disease effectively. A robust healthcare infrastructure, which supports the widespread adoption of new therapeutic modalities and drug delivery systems, will augment the growth of the TB therapeutics market in Europe.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of Tuberculosis
    • 3.2.1.2 Increasing investment for healthcare infrastructure
    • 3.2.1.3 Rise in research and development activities
    • 3.2.1.4 Growing awareness and initiatives
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Technological landscape
• 3.7 Future market trends
• 3.8 Pipeline analysis
• 3.9 Gap analysis
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Vendor matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Active TB
• 5.3 Latent TB

Chapter 6 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 First-line therapy
• 6.3 Second-line therapy

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral
• 7.4 Other route of administration

Chapter 8 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Tablets
• 8.3 Capsules
• 8.4 Injection
• 8.5 Other dosage forms

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Aventis Pharmaceuticals Limited
• 11.2 Bayer Health Care
• 11.3 Eli Lilly And Company
• 11.4 Johnson and Johnson Services; Inc.
• 11.5 Lupin
• 11.6 Macleods Pharmaceuticals Ltd.
• 11.7 Mylan N.V.
• 11.8 Otsuka Pharmaceutical Co., Ltd.
• 11.9 Pfizer Inc.
• 11.10 Sanofi.